+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


  • PDF Icon


  • 17 Pages
  • July 2018
  • Region: Global
  • Citeline
  • ID: 4775390
Drug Overview
Trimbow ([beclomethasone + formoterol + glycopyrrolate]; Chiesi Farmaceutici) is a fixed triple-combination product consisting of glycopyrrolate (a LAMA), formoterol (a LABA), and beclometasone (an ICS), used to relieve the symptoms of moderate to severe chronic obstructive pulmonary disease (COPD). Trimbow’s market potential will ultimately be limited by its restricted geographic scope, as it has only been developed for the European market. Although the drug was the first inhaled corticosteroid/long-acting beta 2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) to launch in the EU, GlaxoSmithKline’s Trelegy Ellipta ([fluticasone furoate + umeclidinium + vilanterol]) was approved just four months later, significantly reducing the impact of Trimbow’s first-to-market status. Further competition will likely come from AstraZeneca’s PT010 ([budesonide + glycopyrrolate + formoterol]), which is expected to launch in the European markets from Q1 2021. The author believes Chiesi Farmaceutici will not seek regulatory approval in the US or Japan, meaning Trimbow will remain limited to the European market.

Table of Contents

Drug Overview
Product Profiles
Trimbow: Chronic obstructive pulmonary disease (COPD)
Figure 55: Tudorza Pressair sales for COPD across the US, Japan, and major EU markets, by country, 2017–26
Figure 67: The authors drug assessment summary of Ultibro/Utibron for COPD
Figure 68: The authors drug assessment summary of Ultibro/Utibron for COPD
Table 1: Trimbow drug profile
Table 2: Trimbow Phase III data in COPD
Table 3: Trimbow Phase III trial in COPD
Table 4: Trimbow sales for COPD across the five major EU markets, by country ($m), 2017–26